Actuate Therapeutics, Inc.
ACTU
$7.22
$0.314.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.48M | 4.58M | 3.66M | 3.40M | 3.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.16M | 26.22M | 27.30M | 27.45M | 24.97M |
| Operating Income | -25.16M | -26.22M | -27.30M | -27.45M | -24.97M |
| Income Before Tax | -27.29M | -28.45M | -28.82M | -27.77M | -24.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.29 | -28.45 | -28.82 | -27.77 | -24.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.29M | -28.45M | -28.82M | -27.77M | -24.74M |
| EBIT | -25.16M | -26.22M | -27.30M | -27.45M | -24.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.49 | -15.22 | -18.97 | -18.66 | -17.19 |
| Normalized Basic EPS | -5.94 | -8.90 | -11.29 | -11.46 | -10.74 |
| EPS Diluted | -10.49 | -15.22 | -18.97 | -18.66 | -17.19 |
| Normalized Diluted EPS | -5.94 | -8.90 | -11.29 | -11.46 | -10.74 |
| Average Basic Shares Outstanding | 33.42M | 15.38M | 6.08M | 5.93M | 5.74M |
| Average Diluted Shares Outstanding | 33.42M | 15.38M | 6.08M | 5.93M | 5.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
